🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

19 recruiting trials

for Malignant Peripheral Nerve Sheath Tumors (MPNST)

Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors NCT04222413Phase 12 sites📍 Fairway📍 Bethesda National Cancer Institute (NCI) · Tests: Metarrestin Surveillance for Malignant Transformation of Neurofibromatosis Type 1 (NF1) Related Peripheral Nerve Sheath Tumors (PNST) NCT06222203n/a1 site📍 Bethesda National Cancer Institute (NCI) MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma NCT06277154Phase 21 site📍 Guangzhou HRYZ Biotech Co. · Tests: MASCT-I, Doxorubicin, Ifosfamide IO Combined With AI as First-line Treatment for Patients With Soft Tissue Sarcoma(TAIS) NCT06849986Phase 21 site📍 Shanghai Fudan University · Tests: Tislelizumab+liposomal doxorubicin+ifosfamide NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) NCT06239272Phase 1, Phase 27 sites📍 Atlanta📍 Chicago📍 Baton Rouge St. Jude Children's Research Hospital · Tests: Surgical resection, Proton beam radiation therapy, Pazopanib, Ifosfamide, Doxorubicin Early Phase Study Evaluating MEK and MDM2 Inhibition in Patients With NF1 and MPNST NCT06735820Phase 1, Phase 22 sites📍 Washington D.C.📍 Dallas AeRang Kim · Tests: APG-115, Selumetinib B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR) NCT04897321Phase 11 site📍 Memphis St. Jude Children's Research Hospital · Tests: Fludarabine, Cyclophosphamide, MESNA, B7-H3 CAR T cells Multi-Institutional Registry for Malignant Peripheral Nerve Sheath Tumors NCT03141021n/a13 sites📍 Tampa📍 Baltimore📍 Bethesda Washington University School of Medicine Trial of Selumetinib and Bromodomain Inhibitor With Durvalumab for Sarcomas NCT05253131Phase 21 site📍 Birmingham University of Alabama at Birmingham · Tests: Selumetinib + ZEN-3694 ± Durvalumab A Study of DEG6498 in Participants With Solid Tumors NCT07244835Phase 13 sites📍 Beijing📍 Beijing📍 Guangzhou Degron Therapeutics Co. · Tests: DEG6498 A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors NCT05985161Phase 216 sites📍 Los Angeles📍 Palo Alto📍 Washington D.C. Memorial Sloan Kettering Cancer Center · Tests: Selinexor SPEARHEAD-3 Pediatric Study NCT05642455Phase 1, Phase 210 sites📍 Palo Alto📍 Bethesda📍 Boston USWM CT, LLC · Tests: Afamitresgene autoleucel A Window of Opportunity Trial of Mirdametinib Plus Vorinostat for NF1 Associated, H3K27 Trimethylation Deficient Malignant Peripheral Nerve Sheath Tumor [MPNST] NCT06693284EARLY Phase 11 site📍 Minneapolis University of Minnesota · Tests: mirdametinib and vorinostat Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors NCT05732831Phase 1, Phase 226 sites📍 Palo Alto📍 Grand Junction📍 Lake Mary Tango Therapeutics, Inc. · Tests: TNG462, Pembrolizumab Safety and Efficacy of BMS-986504 in Unresectable Malignant Peripheral Nerve Sheath Tumor NCT07549022Phase 1, Phase 21 site📍 Cleveland Ankit Mangla, MD · Tests: BMS-986504 A Study of ASTX727 in People With Malignant Peripheral Nerve Sheath Tumors (MPNST) NCT04872543Phase 27 sites📍 Basking Ridge📍 Middletown📍 Montvale Memorial Sloan Kettering Cancer Center · Tests: ASTX727 DoD Award NF230020 Identification of Metabolic Markers and Statistical Prediction of MPNST for Rapid Diagnosis and Assessment of Surgical Margins NCT07298083n/a1 site📍 Houston M.D. Anderson Cancer Center Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion NCT05245500Phase 125 sites📍 Phoenix📍 Lone Tree📍 Jacksonville Bristol-Myers Squibb · Tests: MRTX1719 A First-in-Human Phase I Trial With Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors, Carcinomas and Malignant Peripheral Nerve Sheath Tumors NCT06041516Phase 11 site📍 Bethesda National Cancer Institute (NCI) · Tests: ADCT-701
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy